Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 May 12

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 May 12

language: English

Copper-64 trastuzumab PET imaging: a reproducibility study

Jorge A. CARRASQUILLO 1, 2, Patrick G. MORRIS 3, 4, John L. HUMM 5, Peter M. SMITH-JONES 1, 6, Volkan BEYLERGIL 1, Timothy AKHURST 1, 7, Joseph A. O'DONOGHUE 5, Shutian RUAN 1, Shanu MODI 3, Clifford A. HUDIS 3, Steven M. LARSON 1, 2, 8

1 Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, US; 2 Center for Radioimmunotherapy and Theranostics at Ludwig Center at MSK; 3 Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US; 4 Currently at the Department of Oncology, Beaumont Hospital, Dublin, Ireland; 5 Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, US; 6 Currently at the Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA; 7 Currently at the Peter MacCallum Cancer Centre, Melbourne, Australia; 8 Sloan Kettering Institute, New York, NY, USA


PDF  


BACKGROUND: The current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu)-trastuzumab.
METHODS: An i.v. injection of 296-370MBq/5mg 64Cu-trastuzumab was administered between 1 to 4 h after routine trastuzumab treatment. Whole-body PET scans were performed immediately post-injection and at 24 h post-injection. Serial pharmacokinetics were performed. Of 11 patients (median age of 52; range of 31-61), 8 underwent a repeat study with 64Cu-trastuzumab to assess image and pharmacokinetic reproducibility. Patients were monitored for toxicity.
RESULTS: Patients experienced no allergic reactions or significant adverse effects from 64Cu- trastuzumab. Eight patients successfully completed a repeat 64Cu-trastuzumab study, with acceptable reproducibility of both the biodistribution and pharmacokinetic clearance. Study 1 vs. study 2 showed similar serum concentration post-injection (mean 42.4 + 7.8 %ID/L vs. 44.7 + 12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 h), p>0.5. The volume of distribution (median 2.50L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60L. Of 11 patients, 2 had 64Cu-trastuzumab localization corresponding to known tumor sites—1 in liver and 1 in breast.
CONCLUSIONS: Preliminary results suggest that scanning with 64Cu-trastuzumab is feasible, safe, and reproducible. Tumor uptake of 64Cu-trastuzumab was observed, but tumor detection exhibited low sensitivity in this study in which imaging was performed in the presence of trastuzumab therapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail